Several drug trials illustrated that by suppressing RSK2 expression, the metastasis of human epidermal growth factor receptor 2+ (HER2+) breast cancer was repressed (Mao et al., 2016), the ability of migration and invasion of lung cancer cell was inhibited (Lee et al., 2015), and the carcinogenesis of ultraviolet radiation-induced skin cancer was prevented (Yao et al., 2014). The gene discussed is ERBB2; the disease is breast cancer.